Stoke Therapeutics

Overview

Stoke Therapeutics is a biotechnology company dedicated to developing RNA-based precision medicines aimed at treating severe genetic diseases. Founded in 2014 by Professor Adrian Krainer, Ph.D., Isabel Aznarez, Ph.D., and Huw Nash, Ph.D., the company utilizes proprietary insights into RNA splicing and metabolism pathways to create therapies that address the underlying causes of diseases related to haploinsufficiency.

The company’s TANGO technology platform enables the development of medicines that enhance protein production by modulating RNA splicing. Its lead product candidate, zorevunersen (STK-001), is advancing through clinical trials for Dravet syndrome, a serious genetic epilepsy, while programs for other haploinsufficient diseases such as autosomal dominant optic atrophy (ADOA) are also in development. Stoke Therapeutics remains committed to a patient-centered mission, scientific rigor, and a collaborative workplace culture.

Basic Information

Contact Details

• Phone: +1 781-430-8200
• Website: stoketherapeutics.com
• LinkedIn: linkedin.com/company/stoke-therapeutics

Key Focus Areas & Initiatives

• Biotechnology research
• RNA-based precision medicines
• Genetic disease therapy
• Antisense oligonucleotide therapy
• Ocular gene therapy
• Protein expression technology
• Clinical pipeline development
• Gene expression modulation
• Rare disease treatment
• Neurogenetic disorder solutions
• RNA platform development
• Targeted gene therapy
• Collaborative research initiatives

Technologies Used

• AI
• Google Cloud Hosting
• Google Tag Manager
• Microsoft Office 365
• Mimecast
• Mobile Friendly
• Nginx
• Remote
• WordPress.org